Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
Sponsor
Invivyd, Inc. (Industry)
Overall Status
No longer available
CT.gov ID
NCT06004128
Collaborator
In Expanded Access, treating physicians are the Sponsors (Other)
Study Details
Study Description
Brief Summary
Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Official Title:
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Invivyd, Inc.
- In Expanded Access, treating physicians are the Sponsors
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Invivyd, Inc.
ClinicalTrials.gov Identifier:
NCT06004128
Other Study ID Numbers:
- VYD222-EA-001
First Posted:
Aug 22, 2023
Last Update Posted:
Aug 22, 2023
Last Verified:
Aug 1, 2023
Additional relevant MeSH terms: